ALBUQUERQUE, N.M., June 11 /PRNewswire-FirstCall/ -- Protalex, Inc. (OTC Bulletin Board: PRTX) announced today that Thomas Stagnaro has agreed to join its Board of Directors. Mr. Stagnaro is President and CEO of Agile Therapeutics, a private company focused on developing women's healthcare products. Mr. Stagnaro formerly was president and CEO of 3-Dimensional Pharmaceuticals and Univax Biologics. "Protalex's management recognizes that it is essential to add individuals with strong pharmaceutical experience to its Board of Directors," said John Doherty, President. "We fully expect Tom Stagnaro to provide significant strategic guidance, both in our development of Protalex's bioregulator products and in identifying new opportunities in this market." Mr. Stagnaro began his career with Searle Laboratories and has held increasingly important positions during his 30 years in the pharmaceutical industry. Tom has raised over $200 million for three developmental stage companies and took Univax Biologics public in 1972. His present company, Agile Therapeutics, is a development-stage research-based firm founded in 1997 that is involved in developing novel products for transdermal delivery of pharmaceutical agents. Protalex will soon begin human testing of its unique bioregulator product, which holds promise of actually reversing rather than just palliating the symptoms of autoimmune disease. Initial testing will involve patients with Rheumatoid Arthritis, but Protalex anticipates future validation of the product for the treatment of a wide range of autoimmune diseases. Statements in this press release that are not strictly historical are "forward looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include the Company's limited operating history, uncertainty regarding viability and market acceptance of the Company's products, and the Company's dependence on reimbursement by third parties. These factors and others are more fully described in the section entitled "Risks Related to the Company's Business" in the Company's Registration Statement on Form 10-SB (File No. 00028385) as filed with the Securities and Exchange Commission. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X55477959
SOURCE Protalex, Inc.